Author Year Setting N	Diagnosis; Previous AD courses	Pharmacogenomic test platform; treatment regimen, duration, follow-up	Patient demographics	Remission and response (Guided vs usual care)	Quality of life; Precision	Harms
Singh 2015 ¹³ Setting NR 152	MDD, DSM-5	CNSDose polygene panel and interpretive report: CYP450, UGT1A1 and ABC transporter variants; not yet commercially available; 12 weeks	41% male 44 years Race NR	Remission (HAM-D ≤ 7): 72% vs 28%; RR 2.52 (95% CI 1.71 to 3.73) Response NR	Proportion taking sick leave: Usual care=15% vs guided=4%; RR 1.13 (95% CI 1.01 to1.25)	Intolerability (having an event where patient needed to reduce the dose or stop their antidepressant): Usual care=15% vs guided=4%; RR 1.13 (95% CI 1.01 to 1.25)
Winner 2013 ¹⁴ Outpatient clinic 51	MDD, DDNOS; Mean # previous psychiatric medication trials = 4.4; Mean # psychiatric medications at baseline = 2.8	GeneSight five gene test and interpretive report: CYP2D6, CYP2C10, CYP1A2, SLC6A4, HTR2A; 10 weeks	19.7% male 49.2 years 95% white	Remission (HAM-D≤7 at 10 weeks): 20.0% vs 8.3% (OR=2.75; 95% CI 0.48 to 15.8) Response (50% reduction in HAM-D at 10 weeks): 36.0% vs 20.8% (OR=2.14; 95% CI 0.59 to 7.69)	NR	NR

MDD=Major Depressive Disorder; DDNOS=Depressive Disorder Not Otherwise Specified; HAM-D=Hamilton Rating Scale for Depression; NR=Not reported; RR=Risk Ratio; OR=Odds Ratio